Back to News
Market Impact: 0.2
AIM ImmunoTech Highlights Scientific Rationale, Supportive Data and Continued Advancement of Ampligen® in Pancreatic Cancer in New CEO Corner Video
Source: globenewswire.com
Healthcare & BiotechProduct Launches
The company is advancing its Phase 2 DURIPANC clinical study evaluating Ampligen's potential to reshape the tumor microenvironment and improve checkpoint-inhibitor efficacy. The update reinforces the broader clinical-development strategy but provides no trial efficacy, safety, enrollment, or financial data.
AllMind Terminal
AI-powered research, real-time alerts, and portfolio analytics for institutional investors.
Request TrialMarket Sentiment
Overall Sentiment
mildly positive
Sentiment Score
0.15
More News
- Samsung works to draw iPhone users to its foldables even as Apple enters the market
- Nano-X Imaging (NNOX) Q2 2026 Earnings Call Transcript
- Chewy (CHWY) Q2 2026 Earnings Call Transcript
- Kaplan Fox Encourages Investors of Beta Bionics, Inc. (NASDAQ: BBNX) to Contact the Firm to Learn About Their Legal Rights
- Oil Tops $100 on Supply Fears, Apple Faces a Big Test
- Apple drops its folding iPhone. Our first reaction, plus the other key launch news